Phase 2 N=200 DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
Staphylococcal Bacteraemia
Primary: Desirability of Outcome Ranking (DOOR) — 49; 49; 34; 37 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 ZW25 in Women With Endometrial Cancers
Endometrial Cancer · Carcinosarcoma
Primary: Overall Response Rate/ORR of Participants — 1; 15 Participants
Phase 2 N=17 A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers
Advanced BRAF Mutant Cancers
Primary: Dose-limiting Toxicities (DLTs) — 0 DLTs
Phase 2 N=17 Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA
Vulvar Atrophy
Primary: Number of Subjects With Treatment Emergent Adverse Events — 3; 2; 4; 3 Participants
Phase 2 N=71 Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Small Cell Lung Cancer · Soft Tissue Sarcoma · Triple-negative Breast Cancer
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE V4.03 on Phase 1 — 3; 3; 3; 3 Participants
Phase 2 N=96 Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
Estrogen Receptor Status · HER2/Neu Negative · Invasive Breast Carcinoma
Primary: Tumor Response Rate Defined as 100% Times the Number of Patients Who Meet the Criteria for Complete Response (CR) or Partial Response (PR) Using RECIST Criteria Version…
Phase 2 N=111 A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
Carcinoma, Hepatocellular · Gastric/Gastroesophageal Junction Cancer
Primary: Number of Participants With Adverse Events — 3; 24; 3; 78 Participants
Phase 2 N=58 Effect of Galantamine on Inflammation and Cognition
HIV Associated Cognitive Motor Complex
Primary: Change in Cognition — .018; .12; 0.068; 0.201 Z-score
Phase 2 N=110 GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Maximal Glucagon Concentration During Hypoglycemia — 19.9; 22.5; 82.7 pg/mL
Phase 2 N=66 Pediatric Pain Optimization After Tonsillectomy
Obstructive Sleep Apnea · Tonsillitis · Pain, Procedural
Primary: Total Amount of Opioid Medications Administered — 1.5; 0.9; 0.5 morphine mg equivalents/kg — p=0.045
Phase 2 N=37 Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy
Trigeminal Neuralgia
Primary: Time to Return to Baseline Pain After Injection. — 8; 5 hours — p=0.374
Phase 2 N=77 Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
CMV Infection · Persistent CMV Viremia
Primary: Complete Response — 20; 57 Participants
Phase 2 N=7 CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Myelodysplastic Syndromes
Primary: Number of Participants Achieving Graft-versus-Host Disease-Free and Relapse-Free Survival (GRFS) Through 1 Year Post-Transplant — 4 Participants
Phase 2 N=138 QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
Adenocarcinoma of the Pancreas · Metastatic Pancreatic Cancer · Pancreatic Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs; Phase 1b Portion Only) — 0; 0 Participants
Phase 2 N=49 The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients
Major Depressive Disorder · Bipolar Disorder
Primary: Total Score on the Hamilton Rating Score for Depression (HRSD) - 21 Item Version — 19; 18.5; 10.2; 14.4 Total score on a scale — p=<0.05